500221-80-7

Upstream product

• 103-49-1 dibenzylamine 
• 24498-31-5 (S)-methyl 2-amino-6-(benzyloxycarbonylamino)hexanoate 
• 359781-79-6 Nε-Benzyloxycarbonyl-Nα-isobutyl-L-lysine Methyl Ester 
• 449806-77-3 Nα-isobutyl-Nα-(4-methylbenzenesulfonyl)-L-lysine methyl ester 
• 359781-80-9 Nα-isobutyl-Nα-(4-methylbenzenesulfonyl)-Nε-benzyloxycarbonyl-L-lysine methyl ester 
• 359780-66-8 (S)-6-Benzyloxycarbonylamino-2-[isobutyl-(toluene-4-sulfonyl)-amino]-hexanoic acid benzyl ester 
• 359781-82-1 Nα-Isobutyl-Nε-benzyloxycarbonyl-L-lysine Benzyl Ester 
• 359782-07-3 Nα-isobutyl-Nα-(4-methylbenzenesulfonyl)-L-lysine 
• 24458-14-8 Lys(Z)-OBzl 
• 530-62-1 1,1'-carbonyldiimidazole 

Relevant academic research and scientific papers

Lysine sulfonamides as novel HIV-protease inhibitors: Nε-disubstituted ureas

A series of lysine sulfonamide analogues bearing a Nε-benzylic ureas was synthesized using both solution-phase and solid-phase approaches. A novel synthetic route of Nα-(alkyl)-Nα-(sulfonamides)lysinol using α-amino-caprolactam was developed. Evaluation of these novel protease inhibitors revealed compounds with high potency against wild-type HIV virus.

Lysine sulfonamides as novel HIV-Protease inhibitors: Optimization of the Nε-acyl-phenyl spacer

A series of Nα-isobutyl-Nα-arylsulfonamido-(Nε acyl) lysine and lysinol derivatives were prepared and evaluated as inhibitors of HIV protease and wild type virus. A simple original synthesis was devised to form Nα-(arylsulfonamide)-Nα-isobutyl lysine, whi